about
Mast Cell-Targeted Strategies in Cancer TherapyKIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisChronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical featuresA scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data.Mast cell leukemia with prolonged survival on PKC412/midostaurin.Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposalMast cell leukemia associated with undefined morphology and chronic basophilic leukemiaTyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancyA French National Survey on Clotting Disorders in Mastocytosis.Mastocytosis: a mutated KIT receptor induced myeloproliferative disorderIdentification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816HPaediatric mastocytosis: a systematic review of 1747 cases.Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease.Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.Application of next generation sequencing in the diagnosis and management of mast cell leukemia.Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant).The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation.De novo leukemic variant of mast cell leukemia with KIT D816V.A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17.Myelodysplasia and Mast Cell Leukemia with t(9;22).Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.Incidence, racial disparities and survival outcomes of mast cell malignancies: analysis from a national database.Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia.De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.Natural history and treatment of cutaneous and systemic mastocytosis.Shared clonal cytogenetic abnormalities in aberrant mast cells and leukemic myeloid blasts detected by single nucleotide polymorphism microarray-based whole-genome scanning.KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia.
P2860
Q26743796-746DFD26-A8AA-45C5-BC94-7496A45EDAAFQ26830207-3F8C5DEF-2888-4A95-8252-56472146984EQ27026581-CA83009B-AEC7-46B6-B402-65DD097EFC1EQ31082982-BF57F0B4-1C53-448B-B10B-3B0A5561C0F9Q33898701-FDA70353-3915-4CBC-9885-875BF98F416EQ34137971-3ABBD412-0254-49E5-A667-533BE24D175BQ34253316-1453FFAB-0D7E-4C31-87D1-EC783CE317BCQ34495630-46D7BFBC-D687-43CB-AE4A-4DB1F244B225Q34664111-9A97121B-3C1D-4760-B435-FEEBC7D20A4FQ35685193-6A54FEC2-1B9B-49D4-878E-CE76CE196C79Q36195456-B6E3384A-AAF8-469D-8862-BAE2029624F3Q36210845-52FE561C-E128-4845-9377-AC793648FF3EQ36406996-27D24FED-9C54-4EE1-A461-3E9B4EDD7BB6Q36977300-BC46B41D-A0E3-4387-88E7-4BB2E5E7B5F4Q37354739-DD474792-15CA-4405-81AA-A9A458AB27B2Q37611613-031C1120-C45B-4B3A-83D4-72CCD40CD040Q38348047-42CE129B-406F-4F35-A861-AC46AFC15DC3Q38582624-E1C9A0C6-A365-413B-8BA0-3AFB03F9346FQ38661465-E415DA09-1763-4481-AC51-ED5607C16544Q38866094-E10ADDF3-FC69-4C16-92D8-E3769DE22544Q39779573-3F6BF566-2DE2-4750-81F5-308C43CFC77AQ40063508-5BCB3D5E-82D9-4065-831C-893BA698CB9FQ42131722-0FCA8184-A9C2-4CB3-8AC2-7356299E1AEEQ42234623-D8B44488-972B-4805-B5B0-70A3D8B2AFEFQ42666981-E418F686-2E2D-461F-B85F-30BF4D31A446Q43148956-A9A405E1-44D9-459E-8189-4AB7A2C52E14Q45741179-903C9FDE-1C00-40A9-A7E6-85FCC272BD1EQ47555938-A70CFABC-5798-44BD-86F2-F6000DCB3E58Q47727992-21328CA9-4C4A-4C90-B37B-0ED26A62B0ECQ48277701-4D1D666E-0464-47E3-B022-CB0859F81716Q48319528-8CB4BD92-3279-4B63-92AE-59E6C1D9FD15Q48505281-643B4B24-484B-460E-9FE1-660EF331C221Q49843480-E249E9F2-48F8-4E4B-8B21-D67F7DBDF1DBQ52760297-298C310D-8DC4-4785-B00D-D1FDAF62B184Q52885281-742769B5-98C8-4B45-A677-314AE92FA1ADQ55286285-51270885-CC58-4AE2-98DE-BE3668580868
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mast cell leukemia.
@en
type
label
Mast cell leukemia.
@en
prefLabel
Mast cell leukemia.
@en
P2093
P50
P1433
P1476
Mast cell leukemia.
@en
P2093
Gandhi Damaj
Ludovic Lhermitte
Sophie Georgin-Lavialle
P304
P356
10.1182/BLOOD-2012-07-442400
P407
P577
2012-12-14T00:00:00Z